Search Bar & Filters
Found 12 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of AZD6234 in adults who have obesity or are overweight with at least one weight-related health condition but do not have type 2 diabetes. This Phase III study is randomized, double-blind, and conducted across multiple centers worldwide. Participants will be assigned to receive either AZD6234 or a placebo to compare changes in body weight over 68 weeks of treatment. The study treatments involve subcutaneous injections once a week. Participants will receive one of two doses of AZD6234 or a matching placebo. The trial aims to assess how these treatments affect body weight, waist circumference, triglycerides, blood pressure, and fat mass, including measurements by DXA scans in a subset of participants. The treatment period lasts 68 weeks. During the study, participants will have regular visits for assessments including body weight, waist circumference, blood pressure, and blood tests. Some will have DXA scans to measure fat mass. Researchers will monitor safety and track the percentage change in body weight from the start of treatment. The total participation duration includes 68 weeks of treatment with monitoring at specified intervals.
Actively Recruiting
This research investigates the use of ultrasound techniques to guide treatment in adults with heart failure who are seen in outpatient settings. The study aims to evaluate whether managing heart failure using pulmonary ultrasound and inferior vena cava assessments can improve a combined clinical and biological outcome within 30 days, including changes in natriuretic peptide levels. It also explores the impact of this guided approach on risks of cardiovascular death and hospitalization. Participants are randomly assigned to one of two groups one receiving heart failure treatment guided by lung and inferior vena cava ultrasound results, and the other receiving usual care without ultrasound guidance. The choice of treatment modifications is left to the investigators following European guidelines. The study is open-label and conducted across multiple centers. During the study, participants will have ultrasound assessments and blood tests to measure natriuretic peptides at the start and after 30 days. Researchers will also evaluate clinical signs of congestion and track events such as cardiovascular death or hospitalization within 30 days. Patients will be regularly monitored to assess changes in ultrasound congestion and corresponding biomarkers throughout the study period.
Actively Recruiting
Researchers are studying patients with community-acquired pneumonia who need oxygen therapy due to acute respiratory distress and low blood oxygen levels. This research aims to see if placing patients in a prone position lying face down while they receive nasal high flow oxygen can reduce the need for intubation and improve outcomes. The study particularly excludes patients with COVID-19 and focuses on non-COVID pneumonia cases. Participants will be randomly assigned to one of two groups. One group will be encouraged and assisted to lie in the prone position for at least 8 hours per day in multiple sessions, aiming for up to 16 hours if tolerated. The other group will receive usual care with nasal high flow oxygen therapy but no prone positioning. Both groups will have oxygen levels monitored and care adjusted to maintain target oxygen saturation. During the study, patients will be observed for intubation rates within 28 days, comfort levels during prone positioning, oxygenation changes, time to escalation of breathing support, and overall outcomes including mortality up to 90 days. Safety measures like skin and infection monitoring will also be recorded. Quality of life will be assessed at 90 days and 5 years, with nursing workload tracked within the first day after randomization.
Actively Recruiting
Researchers are studying children under 16 years old with spinal muscular atrophy SMA who are treated with therapies that restore SMN protein, such as nusinersen, risdiplam, or onasemnogene abeparvovec. The goal is to describe new types of SMA in these treated patients over two years, evaluate tools used to monitor the disease, and collect information on the overall costs associated with SMA in France. Participants receive SMN restoring therapies and are followed for two years with regular assessments every six months. These evaluations include muscle function tests, cognitive assessments, cardiac checks, MRI scans when possible, fatigue and activity monitoring, bulbar function tests, body composition and metabolism measurements, questionnaires on quality of life, and optional blood and cerebrospinal fluid sample collections. The study tracks disease progression at muscular, cognitive, orthopedic, respiratory, metabolic, cardiac, and bulbar levels. During the study, participants undergo various tests and questionnaires at multiple time points from the start up to 24 months. These include muscle strength measurements, developmental and behavioral assessments, heart exams, body scans, fatigue monitoring, swallowing evaluations, and quality of life surveys. Optional biological samples are collected periodically. The study carefully records disease markers and functional changes while monitoring participants wellbeing and impact on families throughout the two-year period.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
Actively Recruiting
The research focuses on childbirth, a significant event for women, aiming to assess maternal satisfaction during delivery and postpartum. The study explores how different epidural anesthesia approaches impact womens childbirth experiences, recognizing that negative birth experiences can lead to psychological and physical issues like postpartum depression and chronic pelvic pain. This observational study compares conventional epidural methods to newer ambulatory epidural techniques using modern pharmacological protocols. Participants will be observed during two periods before and after changes in epidural practice. In the before period, women receive conventional epidural anesthesia with local anesthetics and opioids. In the after period, an ambulatory epidural is used, involving lower doses that allow patients to walk while monitored. Both groups follow department protocols. Women complete the Childbirth Assessment Questionnaire QEVA 2 days after birth and again 4 weeks postpartum to provide feedback on their delivery and postpartum experience. During the study, participants childbirth experiences are captured by the QEVA questionnaire administered in hospital and via phone. Researchers assess maternal satisfaction, relationships with nursing staff, early mother-child bonding, and safety factors such as delivery room time, instrumental extraction needs, emergency cesarean rates, spontaneous urination ability, and ambulation safety. The study spans from delivery through 4 weeks postpartum, gathering detailed feedback and safety data to evaluate the impact of epidural techniques on maternal outcomes.
Actively Recruiting
Researchers are investigating the use of fecal microbiota transplantation FMT capsules as a way to clear multi-drug resistant and extensively drug-resistant Gram-negative bacteria MDR-GNB from the gut. These bacteria are a serious global health threat because they increase the risk of infections and spread easily in healthcare and community settings. This phase III randomized controlled trial aims to see if FMT capsules can effectively decolonize patients carrying carbapenem-resistant or extended-spectrum beta-lactamase producing Enterobacteriaceae, which currently have limited treatment options. The study compares two groups one receiving FMT capsules made from healthy donor stool processed and frozen into capsules, and the other receiving placebo capsules containing only the solution used in FMT preparation. Participants will take 50 capsules in one day. This capsule form helps reduce side effects and supports outpatient treatment. The trial will assess the effect of FMT capsules versus placebo on bacterial decolonization and infection prevention over time. Participants will be monitored through stool cultures taken at the start, 30 days, and 90 days after treatment to check for bacterial clearance. Secondary assessments will track infection rates, safety, and tolerability for up to two years. The study includes detailed monitoring of microbiological and clinical outcomes, with the primary measure being clearance of MDR-GNB at 30 days post-randomization. The total follow-up may extend to two years to evaluate long-term effects and safety.
Actively Recruiting
Researchers are evaluating two different locoregional anesthesia techniques to manage postoperative pain and aid recovery after a midline laparotomy, a type of abdominal surgery. This randomized controlled trial compares the commonly used epidural analgesia with a newer method called bilateral rectus sheath block. The study aims to understand how these pain relief methods influence patients quality of recovery after surgery, measured by the Quality of Recovery-15 score. Participants are randomly assigned to one of two groups one receiving thoracic epidural analgesia, where a catheter is placed in the epidural space to deliver local anesthetic, and the other receiving bilateral rectus sheath block under ultrasound guidance, with anesthetic delivered via catheters on both sides of the abdomen. Both groups undergo the same type of abdominal surgery, and the treatments are part of a multimodal pain management approach during and after surgery. During the study, patients will be monitored for changes in recovery quality on postoperative days 1, 2, and 3, as well as the day before surgery. Assessments include pain control effectiveness, blood pressure effects, nausea, complications related to the analgesic technique, length of hospital stay, bowel function, morphine use, and patient satisfaction up to 30 days after surgery. Catheter placement success, mobility, and other postoperative events are also tracked to understand the impact of each anesthesia method on rehabilitation.
Actively Recruiting
This research investigates the urinary excretion patterns of gadolinium-based contrast agents Gd-CAs used in magnetic resonance imaging MRI. Gadolinium, a rare earth element, is toxic in its isolated form but is safely used in complex molecules as contrast agents to enhance MRI images. The study aims to understand how these agents are eliminated through urine shortly after MRI and explores the potential for recovering gadolinium from urine to reduce environmental contamination. Participants prescribed MRI scans with gadolinium contrast agents will have urine samples collected before the injection and multiple times within two and a half hours after receiving the contrast agent. Blood samples are also collected before injection to assess renal function. This single-group study focuses on describing the elimination kinetics of gadolinium contrast agents via urine following MRI. Participants will provide blood and urine samples around the time of their MRI scan. Researchers will monitor urinary excretion of gadolinium at two and a half hours post-injection and measure factors such as renal function, beverage intake volume, and timing of the first spontaneous urination. The study also tracks refusal rates and premature exits. Participation involves sample collections at the MRI visit, with total study duration centered on the immediate post-injection period.
Actively Recruiting
Researchers are exploring the use of transcutaneous auricular vagal nerve stimulation taVNS to help adolescents with non-suicidal self-injury NSSI disorder, a behavior characterized by intentional self-harm without suicidal intent. NSSI is prevalent among adolescents, especially following the COVID-19 crisis, and current drug treatments lack solid scientific support. The study aims to see if taVNS, which may improve stress regulation through the hypothalamic-pituitary axis by stimulating the vagus nerve, can be accepted and used regularly by adolescents. Participants will use a device called TENS ECO PLUS along with a vagus nerve ear electrode to deliver taVNS for 10 minutes twice daily or 20 minutes once daily over eight consecutive weeks. The treatment period is from week 2 to week 10 after inclusion, with follow-up continuing until week 22. Researchers will assess how well adolescents adhere to this at-home treatment and monitor any changes in the frequency of self-injury, anxiety, depression, and side effects. During the study, participants will be monitored for treatment adherence, frequency of self-injury episodes weekly from two weeks before treatment through 20 weeks after, and psychological symptoms at several time points. Safety and patient experiences with taVNS will also be evaluated. The total participation lasts approximately 22 weeks, allowing detailed observation of treatment effects and user adherence.
1-10 of 12
1